Share Name Share Symbol Market Type Share ISIN Share Description
Ixico Plc LSE:IXI London Ordinary Share GB00BFXR4C20 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.0% 70.50 69.00 72.00 70.50 70.50 70.50 30,719 08:00:00
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 5.4 -0.8 -2.0 - 33

IXICO plc Directorate Change

22/08/2019 7:02am

UK Regulatory (RNS & others)


Ixico (LSE:IXI)
Historical Stock Chart

3 Months : From Aug 2019 to Nov 2019

Click Here for more Ixico Charts.

TIDMIXI

RNS Number : 6728J

IXICO plc

22 August 2019

22(nd) August 2019

IXICO plc

("IXICO" or the "Company")

Directorate changes

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, today announces two directorate changes.

As anticipated, Grant Nash, who was appointed as CFO on 29 April 2019, will join the board with immediate effect. In his executive director role, Grant leads the Company's Finance, Legal and IT functions. Grant joined IXICO from UK Biobank, a national and international health research data resource, where he had been Finance Director since 2014.

Tim Sharpington, who has served as non-executive director and senior independent director since October 2013, has informed the Company of his intention to step down from the board at the end of the current financial year to focus on his executive responsibilities elsewhere. His responsibilities as IXICO's senior independent director and chair of the remuneration committee will be assumed by Mark Warne, currently a non-executive director.

Following the directorate changes the Company will have two executive directors and three independent non-executive directors.

Giulio Cerroni, Chief Executive Officer of IXICO, commented: "Grant's appointment to the board reflects the substantial contribution he has already made to IXICO since his appointment as CFO on 29(th) April 2019. He has brought strong financial leadership skills combined with a deep appreciation of operational excellence at a time of significant revenue growth and an accelerated path to profitability. Separately, I would like to thank Tim for all his counsel and guidance to me personally since I joined the company and wish him well for the future."

Charles Spicer, Chairman of IXICO, commented: "On behalf of the board and personally, I would like to thank Tim warmly for his many years of service to the Company and the board. Since its admission to AIM in 2013, he has guided and supported IXICO through a number of strategic challenges and changes. In that time, the Company has significantly enhanced its position in providing specialist data analytics for neuroscience drug development and more than doubled revenues over the last three years. We all wish him well for his future endeavours."

Pursuant to Schedule 2 (g) of the AIM Rules for Companies, Grant Robert Nash (aged 42) has held the following directorships or partnerships in the past five years:

 
 Current                 Previous 
  The Leach Fourteenth   None 
   Trust 
   Golden Bay Mansions 
   Limited 
                        --------- 
 

Mr Nash does not currently hold any shares in the Company.

There is no further information required to be disclosed in respect of the above appointment pursuant to Rule 17 and Schedule 2 (g) of the AIM Rules for Companies.

For further information please contact:

 
 IXICO plc                                        +44 (0) 20 3763 7498 
 Giulio Cerroni, Chief Executive Officer 
  Grant Nash, Chief Financial Officer 
 Cenkos Securities PLC (Nominated adviser 
  and sole broker)                                +44 (0) 20 7397 8900 
 Giles Balleny / Max Gould (Corporate Finance) 
 Michael F Johnson / Russell Kerr (Sales) 
 Optimum Strategic Communications                  +44 (0) 203 950 9144 
 Mary Clark / Anne Marieke Ezendam / Supriya 
  Mathur 
 IXICO@optimumcomms.com 
 

About IXICO

IXICO is dedicated to delivering insights in neuroscience. Our mission is to transform the progression of our biopharmaceutical clients' neurological therapeutic pipelines through the application of novel imaging and digital biomarkers.

IXICO's data analytics services are used by the global biopharmaceutical industry to interpret data from brain scans and digital biosensors to enable better trial design, site qualification, patient selection and clinical outcomes. We provide technology-enabled services across all phases of clinical evaluation. Our integrated digital platform provides a scalable and secure infrastructure for the capture and analysis of regulatory compliant clinical data to enable clients to make rapid, better informed decisions. IXICO is also collaborating with partners to develop new analytical techniques and companion digital health products targeted at improving patient outcomes.

More information is available on www.IXICO.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

BOAMMGZRFGNGLZM

(END) Dow Jones Newswires

August 22, 2019 02:02 ET (06:02 GMT)

1 Year Ixico Chart

1 Year Ixico Chart

1 Month Ixico Chart

1 Month Ixico Chart
Your Recent History
LSE
IXI
Ixico
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20191121 21:03:02